Makale detayı · 2022
Combined resveratrol and vitamin D treatment ameliorate inflammation-related liver fibrosis, ER stress, and apoptosis in a high-fructose diet/streptozotocin-induced T2DM model
Dergi
Springer Science and Business Media LLCISSN 0948-6143
ISSN kaydı başka bir dergiye işaret ediyor; ad YÖKSİS kaydından.
YÖKSİS
OpenAlex
SJR Q1
JCR Q2
Atıf 30
Üst %10
Yüzdelik 92.6%
FWCI 2.89
- Yıl
- 2022
- Tür
- article
Veri kaynağı ayrımı
- YÖKSİS YÖKSİS makale kaydı
- YÖKSİS dergi adı Springer Science and Business Media LLC
- Katalog eşleşmesi (ISSN) Histochemistry and Cell Biology
- OpenAlex OpenAlex zenginleştirmesi (özet, atıf, konular)
Özet
Özet henüz derlenmedi; DergiPark / OpenAlex kuyruğu işlenince burada görünecek.
Konular
Atıflar
OpenAlex cited_by_count. WoS veya Scopus atıf sayısı değildir; o kaynaklar için ayrı kolon yoktur.
30 atıf
OpenAlex cited_by_count (önbellek / veritabanı)
Yerel katalogda bu makaleye atıf yapan 20 yayın (OpenAlex referans eşleşmesi; tam dünya listesi değildir).
- The impact of the endocrine-disrupting chemicals on the glucose-6-phosphate dehydrogenase enzyme activity 2023
- Revealing the secrets of Blue Zones 2024
- Vitamin D in Behcet’s Disease, a Brief Review of the Literature 2022
- Experimental Approaches to Diabetes Mellitus 2022
- The impact of the vitamin D and resveratrol administration on the stiffness and elasticity of T2DM rat aorta associated with the trace element and mineral levels 2024
- The impact of the vitamin D and resveratrol administration on the stiffness and elasticity of T2DM rat aorta associated with the trace element and mineral levels 2024
- The impact of the vitamin D and resveratrol administration on the stiffness and elasticity of T2DM rat aorta associated with the trace element and mineral levels. 2024
- Malus floribunda Siebold ex Van Houtte Fruit Extract Mitigates Fructose/Streptozotocin Induced Type 2 Diabetes in Rats. 2026
- A comparative study to assess two doses of a novel aldose reductase inhibitor (ARI)/Antioxidant drug candidate Cemtirestat, the current ARI drug Epalrestat, and the antioxidant Stobadine on Fructose- and Streptozotocin-Induced hepatic and pancreatic stress responses in rats 2025
- A comparative study to assess two doses of a novel aldose reductase inhibitor (ARI)/Antioxidant drug candidate Cemtirestat, the current ARI drug Epalrestat, and the antioxidant Stobadine on Fructose- and Streptozotocin-Induced hepatic and pancreatic stress responses in rats 2025